Targeting mesenchymal monocyte-derived macrophages to enhance the sensitivity of glioblastoma to temozolomide by inhibiting TNF/CELSR2/p65/Kla-HDAC1/EPAS1 axis
Journal of Advanced Research · 2026-02 · 80 · 925-941
DOI: 10.1016/j.jare.2025.05.032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Advanced Research, 2026-02. Verfasst von Wei Gao und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, China; The Key Laboratory of …. Hauptthemen laut MEDLINE: Temozolomide, Glioblastoma, Drug Resistance, Neoplasm, Macrophages. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for Central Universities of the Central South University.
Abstract (Originalsprache)
INTRODUCTION: Temozolomide (TMZ) resistance poses a significant challenge to the treatment of aggressive and highly lethal glioblastomas (GBM). Monocyte-derived Macrophages (MDM) within the tumor microenvironment are key factors contributing to TMZ resistance in GBM. Lactate-mediated histone lysine lactylation (Kla) plays a crucial role in the regulation of tumor progression. However, the mechanism through which MDM-induced Kla expression promotes TMZ resistance in GBM remains unclear. OBJECTIVES: The objective of this study s to identify a subtype of MDM with therapeutic potential target and to elucidate the mechanisms through which this subtype of MDM contributes to tumor malignant progression and TMZ resistance. METHODS: We integrated single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics data to evaluate whether mesenchymal (MES) MDM is associated with poor prognosis. By establishing a subtype model of GBM cells for the first time, we validated the mechanism by which MES-MDM promotes subtype conversion of tumor cells. Using patient-derived GBM organoids and an intracranial orthotopic GBM model, we demonstrated that targeting MES-MDM increased GBM sensitivity to TMZ treatment. RESULTS: We identified a novel MDM subtype, MES-MDM, in the hypoxic niches of the perinecrotic region characterized by high TREM1 expression, which fueled GBM progression. Hypoxia drived MES-MDM signatures by activating ATF3 transcription. MES-MDM facilitated the transition from the NPC to the MES subtype in GBM cells, in which Histone Deacetylase 1 (HDAC1) Kla, induced by the TNF-CELSR2/p65 signaling pathway, promoted this conversion, thereby promoting TMZ resistance. Targeting MES-MDM with TREM1 inhibitory peptides amplified TMZ sensitivity, offering a potential strategy for overcoming resistance to therapy in GBM. Targeting TREM1 enhanced the effectiveness of anti-PD-1 immunotherapy. CONCLUSION: This study provides a potential therapeutic strategy for patients with MES-subtype GBM by targeting MES-MDM in combination with TMZ or PD-1 antibody treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, China; The Key Laboratory of Carcinogenesis of the Chinese Ministry of Health, The Key Laboratory o…
- Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
- Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China. Electronic address: liuqingdr@csu.edu.cn.
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for Central Universities of the Central South University
Zitieren
APA
Gao, W., Long, X., Lin, X., Deng, K., Li, D., Huang, M., Wang, X., Liu, Q., & Wu, M. (2026). Targeting mesenchymal monocyte-derived macrophages to enhance the sensitivity of glioblastoma to temozolomide by inhibiting TNF/CELSR2/p65/Kla-HDAC1/EPAS1 axis. Journal of Advanced Research, 80, 925-941. https://doi.org/10.1016/j.jare.2025.05.032
Vancouver
Gao W, Long X, Lin X, Deng K, Li D, Huang M, et al. Targeting mesenchymal monocyte-derived macrophages to enhance the sensitivity of glioblastoma to temozolomide by inhibiting TNF/CELSR2/p65/Kla-HDAC1/EPAS1 axis. Journal of Advanced Research. 2026;80:925-941. doi:10.1016/j.jare.2025.05.032
BibTeX
@article{Gao2026,
author = {Gao, Wei and Long, Xinmiao and Lin, Xiang and Deng, Kun and Li, Danyang and Huang, Meng and Wang, Xiangyu and Liu, Qing and Wu, Minghua},
title = {Targeting mesenchymal monocyte-derived macrophages to enhance the sensitivity of glioblastoma to temozolomide by inhibiting TNF/CELSR2/p65/Kla-HDAC1/EPAS1 axis},
journal = {Journal of Advanced Research},
year = {2026},
volume = {80},
pages = {925--941},
doi = {10.1016/j.jare.2025.05.032}
}
EUVIMED